Safety and performance of the EverProTM everolimus-eluting coronary stent system with biodegradable polymer in a real-world scenario

作     者：Rahul Trimukhe Preeti Vani Arvind Patel Vikas Salgotra 

作者机构：Department of CardiologyAtma Malik HospitalAhmednagar 423601MaharashtraIndia SLTL Medical DivisionSLTL(Sahajanand Laser Technology Ltd.)Gandhinagar 382016GujaratIndia SLTL GroupSLTL(Sahajanand Laser Technology Ltd.)Gandhinagar 382016GujaratIndia 

出 版 物：《World Journal of Cardiology》 (世界心脏病学杂志（英文版）（电子版）)

年 卷 期：2020年第12卷第12期

页      面：615-625页

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：Coronary artery disease Everolimus Major adverse cardiac event Retrospective,EverPro^(TM),Myocardial infarction 

摘      要：BACKGROUND The EverProTM(Sahajanand Laser Technology Ltd.,India)everolimus-eluting coronary stent system(EES)is a second-generation drug-eluting stent with a biodegradable *** To determine the safety and performance of the EverProTM EES in patients with coronary artery disease(CAD)during a 1-year clinical *** This observational,retrospective,single-center study enrolled patients who had been implanted with the EverProTM stent between June 1,2018 and January 31,2019,and had completed a 1-year follow-up period after the index *** primary clinical endpoint was major adverse cardiac events(MACE)at 6 mo defined as the composite of cardiac death,myocardial infarction(MI),and target lesion revascularization(TLR).Secondary endpoints were the incidence of TLR at 1,6 and 12 mo follow-up,MACE at 1 and 12 mo follow-up,and stent thrombosis up to 1 year after the index *** The study population comprised 77 patients(98 lesions).A total of 37(48.1%)patients had comorbid *** total,26(33.8%)patients presented with ST segment elevation MI and 10.4%patients with non-ST segment elevation *** lesions were located mainly in the left anterior descending artery(49%)followed by the right coronary artery(29.6%),left circumflex(12.2%)and obtuse marginal(9.2%)*** majority of patients were with single-vessel disease(79%),22.2%of lesions had a mild to severe thrombus load,and 94.9%were American College of Cardiology/American Heart Association type B or *** novo stenting was performed in 96.9%of patients and 3%were treated for in-stent *** success was attained in all ***-hospital or followup MACE and stent thrombosis were not reported during the 1-year follow-up *** These findings suggest that the EverProTM EES is a safe and effective treatment option with no MACE or stent thrombosis reported during the 1-year study period in patients with CAD.